Catalyst Pharmaceuticals, Inc.

NASDAQ:CPRX

Biotechnology

Healthcare
$31.49 -0.03%

-$0.01 today

Market cap
$3.85B
Beta
0.74
P/E (TTM)
17.3
EPS (TTM)
$1.81
52W Low $19.05High $32.56

Volume 0.00M

Average 2.17M

CPRX Other Stockholders Equity

Equity items not reported separately, such as additional paid-in capital or treasury stock.

Catalyst Pharmaceuticals, Inc.NASDAQ: CPRX

Other Stockholders Equity · Q1 FY2026 · quarter ended Mar 2026

Other stockholders equity remains negative

Q1 FY2026 other stockholders equity was $0, compared with $0 a year earlier.

Context

  • Other stockholders equity amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Other stockholders equity increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Other Stockholders Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Stockholders Equity history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Other Stockholders Equity vs competitors

How CPRX compares with its peers on the latest reported figures

  • CPRX's Mar 2026 other stockholders equity of $0 is the highest of the 9 companies compared; the peer median is $0.
  • Other stockholders equity amounts to 0.0% of total assets for CPRX, versus a peer median of 0.0%.
CPRX Competitors Peer median
Other Stockholders Equity for CPRX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CPRXCatalyst Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
SRRKScholar Rock Holding CorporationSep 2026$0 ——0.0%
KNSAKiniksa Pharmaceuticals, Ltd.Jun 2026$0 ——0.0%
ADPTAdaptive Biotechnologies CorporationJun 2026$0 ——0.0%
IDYAIDEAYA Biosciences, Inc.Mar 2026$0 ——0.0%
BEAMBeam Therapeutics Inc.Jun 2026$0 ——0.0%
AGIOAgios Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
MLYSMineralys Therapeutics, Inc.Jun 2026$0 ——0.0%
RXRXRecursion Pharmaceuticals, Inc.Jun 2026$0 ——0.0%
Peer median (excluding CPRX) $0——0.0%

Competitors are the stored peer set for CPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents171.45M298.4M137.64M517.55M709.17M
Short-term Investments19.82M0000
Net Receivables6.72M10.79M53.51M65.49M128.27M
Inventory7.87M6.81M15.64M19.54M37.17M
Other Current Assets327K0489K1.03M2.04M
Total Current Assets210.11M320.81M219.33M623.61M894.03M
Property, Plant & Equipment (Net)3.98M3.62M3.7M3.58M2.97M
Goodwill00000
Intangible Assets032.47M194.05M156.67M131.67M
Long-term Investments0016.49M21.56M22.54M
Tax Assets23.7M18.74M36.54M45.98M55.6M
Other Non-current Assets9K0000
Total Non-current Assets27.68M54.82M250.79M227.8M212.78M
Total Assets237.79M375.63M470.11M851.41M1.11B
Account Payables2.77M3.98M14.8M16.59M11.2M
Short-term Debt0000437K
Tax Payables79K8.7M729K894K0
Deferred Revenue00000
Other Current Liabilities4.28M5.37M51.29M11.16M122.76M
Total Current Liabilities27.06M57.59M76.06M120.68M147.15M
Long-term Debt00000
Deferred Tax Liabilities00002.83M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities014.06M2.98M315K209K
Total Non-current Liabilities3.89M17.62M6.17M3.1M5.39M
Total Liabilities30.96M75.21M82.23M123.78M152.54M
Common Stock103K105K107K121K123K
Retained Earnings(26.31M)49.86M121.27M285.16M474.19M
Accumulated OCI(148K)24K14K64K0
Other Stockholders Equity00000
Minority Interest00000
Total Equity206.83M300.42M387.88M727.63M954.27M
Total Debt4.2M3.89M3.56M3.19M2.79M
Net Debt(167.24M)(294.5M)(134.08M)(514.37M)(706.38M)

Catalyst Pharmaceuticals, Inc.

NASDAQ:CPRX

Intrinsic Alpha fair value

Locked

Current Price

$31.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.